Arrowhead Pharmaceuticals, Inc. develops medicines for the treatment of intractable diseases in the United States. The company's product pipeline includes Plozasiran, which has completed Phase 3 clinical trial to treat hypertriglyceridemia, dyslipidemia, and familial chylomicronemia syndrome; Olpasiran that is in Phase 3 clinical trial to reduce the production of apolipoprotein A; and Fazirsiran that is in Phase 3 clinical trial for the treatment of liver disease associated with alpha-1 antitrypsin deficiency. It also develops Zodasiran that is in Phase 2b clinical trial for the treatment of dyslipidemia and hypertriglyceridemia; GSK-4532990 to treat metabolic-dysfunction associated steatohepatitis (MASH); and Daplusiran/Tomligisiran which is in Phase 2 clinical trial for the treatment of Chronic Hepatitis B. In addition, the company is developing ARO-PNPLA3, which is in Phase 1 clinical trial to treat patients with MASH; ARO-INHBE to reduce the hepatic expression of the INHBE gene and its secreted gene product; ARO-RAGE to treat inflammatory lung disease; ARO-MUC5AC to treat muco-obstructive pulmonary diseases; and ARO-MMP7 for the treatment of idiopathic pulmonary fibrosis that is in Phase 1/2a clinical trials. Further, it develops ARO-DUX4 for the treatment of facioscapulohumeral muscular dystrophy; ARO-DM1 to treat patient with Type 1 Myotonic Dystrophy; ARO-C3 to treat complement-mediated renal disease; ARO-CFB for the treatment of complement-mediated kidney disease that is in Phase 1/2a clinical trial; and ARO-ATXN2 for the treatment of Spinocerebellar Ataxia Type 2 that is in Phase 1 clinical trial. Arrowhead Pharmaceuticals, Inc. has collaboration and license Agreements with Glaxosmithkline Intellectual Property (No. 3) Limited; Horizon Therapeutics Ireland DAC; Takeda Pharmaceutical Company Limited; and with Amgen Inc. The company was founded in 2003 and is headquartered in Pasadena, California.

Arrowhead Pharmaceuticals Inc.

Arrowhead Pharmaceuticals ( ($ARWR) ) has issued an announcement. On June 12, 2026, Arrowhead Pharmaceuticals appointed Dr. Matt Cohen, M.D., M.B.A...

Arrowhead Pharmaceuticals Adds Experienced Healthcare Investor to Board

NY, WSW, June 1st, 2026, FinanceWire Peptides are having a moment – and for good reason. They represent one of the most productive frontiers in mod...

Entera Bio Is Building the Future of Peptides Beyond the Needle (NASDAQ: ENTX)

Arrowhead Pharmaceuticals, Inc. ($ARWR) announced an update on their ongoing clinical study. Arrowhead Pharmaceuticals, Inc. is running a Phase 2a ...

Arrowhead’s Inhaled ARO-RAGE Asthma Trial Enters Active Recruitment, Keeping a Key Pipeline Catalyst in Play

Arrowhead Pharmaceuticals, Inc. ($ARWR) announced an update on their ongoing clinical study. The study, titled “A Phase 1/2a Dose-Escalating Study ...

	A	B	C	D
1	Symbol	Price	Change	Volume
2	ARWR	$81.82	+0.96%	3.86M
3
4
5

	A	B	C	D
1	Symbol	Price	Change	Vol
2	ARWR	$81.82	+1.0%	3.86M
3
4
5
6

ARWR

ARWR

Recent News for ARWR

Get Arrowhead Pharmaceuticals Inc. Data in Excel

Get Arrowhead Pharmaceuticals Inc. Data in Excel